Ticker Scout
← tickerscout.ai

UnitedHealth Group Incorporated (UNH)

CIK 0000731766 · NYSE · Latest period: Q3 FY2026 (ended 2026-09-30, 10-Q accession 0000731766-26-000266) · Annual report: FY2025 10-K (filed 2026-03-02, accession 0000731766-26-000062) · Next expected filing: 10-K ~2027-03-01

PeriodQ3 FY2026Q2 FY2026

Published

MetricAmountvs. year ago
Revenue$112,694,000,000down 0.4%
Net earnings to shareholders$4,110,000,000up 75.0%
Diluted EPS$4.56up 76.1%
Earnings from operations$6,563,000,000up 52.1%
Medical care ratio88.4%down 1.5 points

Company details

NameUnitedhealth Group Inc
TickerUNH
CIK0000731766
ExchangeNYSE
StateMinnesota
IncorporationDelaware
SIC6324
OfficeFinance
IndustryHospital & Medical Service Plans
Latest period coveredQ3 FY2026, ended 2026-09-30, 10-Q, accession 0000731766-26-000266
Fiscal year end12/31 (MM/DD)
Next expected filing10-K around 2027-03-01 (predicted)

AI synthesis of five filings for UnitedHealth Group Incorporated

Fiscal Q3 2026 (quarter ended September 30, 2026). Amounts are in US dollars.

Business

From the FY2025 Annual Report on Form 10-K, accession 0000731766-26-000062.

UnitedHealth Group is a diversified US health care company run as two businesses: UnitedHealthcare, which sells health insurance and benefits to employers, individuals, Medicare beneficiaries and state Medicaid programs, and Optum, which delivers care, runs a pharmacy benefit manager and sells data, technology and services to the health system. Most of the money comes from premiums: of 2025 revenues of $447.6 billion, premiums were $352.2 billion, products (mainly pharmacy) $53.4 billion, services $38.0 billion and investment and other income $3.9 billion. Premiums from risk-based products make up nearly 80% of consolidated revenue, and premiums paid by the federal Centers for Medicare & Medicaid Services (CMS) alone were 44% of 2025 revenue, most of it earned by the Medicare business. The company is therefore, above all, a bet on pricing medical risk correctly and on government program funding.

It reports four segments. Optum's businesses sell substantially to UnitedHealthcare and to one another, so segment revenues overlap: in 2025 they summed to well above the consolidated total, before $168.0 billion of eliminations.

  • UnitedHealthcare (2025 revenue $344.9 billion) is the benefits business, organized in three units:
    • Employer & Individual ($79.2 billion) covered 29.7 million people at December 31, 2025. It sells both risk-based plans, where it takes medical cost risk for a fixed monthly premium, and fee-based administrative services for self-funded employers.
    • Medicare & Retirement ($171.3 billion) served 8.4 million Medicare Advantage members, 10.4 million Part D enrollees (2.8 million of them in stand-alone drug plans) and 4.3 million Medicare Supplement members. Medicare Advantage premiums from CMS vary by where members live, their demographics and their health status.
    • Community & State ($94.4 billion) runs Medicaid, CHIP, dual-eligible and long-term care programs in 32 states and the District of Columbia, serving nearly 7.4 million people.
  • Optum Health (2025 revenue $102.0 billion) delivers primary, specialty, surgical, in-home, behavioral and virtual care to about 95 million consumers (as reported before the 2026 realignment described below). Much of it is under fully accountable value-based arrangements, where Optum Health takes responsibility for patients' total health care costs in exchange for a monthly premium; the rest is fee-based or fee-for-service.
  • Optum Insight (2025 revenue $19.4 billion) sells data, analytics, software, revenue-cycle, payment-integrity and managed services to hospitals, physicians, health plans, state governments and life sciences companies. Its contracted backlog was about $31.1 billion at December 31, 2025, of which $18.3 billion was expected within 12 months and $12.9 billion was with affiliates. It was $32.8 billion a year earlier.
  • Optum Rx (2025 revenue $154.7 billion) is the pharmacy benefit manager and pharmacy business. It runs a network of about 64,000 retail pharmacies plus home delivery, specialty, community and infusion pharmacies, and in 2025 it managed $188 billion of drug spending, including nearly $87 billion of specialty drugs.

On January 1, 2026 the company moved Optum Financial, including Optum Bank, from Optum Health to Optum Insight; 2026 segment figures recast the prior year on that basis. Optum Financial had nearly 26 million consumer accounts and more than $27 billion of assets under management at December 31, 2025. The company had more than 390,000 employees at year-end 2025, nearly 165,000 of them clinical professionals.

Regulation shapes the whole business. Insurance and HMO subsidiaries are licensed and capital-regulated state by state, which limits the dividends they can pay to the parent. CMS sets Medicare Advantage rates and audits risk-adjustment coding. States set Medicaid rates and award contracts by bid. Optum Rx is subject to federal and state pharmacy benefit manager laws, and Optum Bank is supervised by Utah regulators and the FDIC. The company competes with everyone from start-ups to Fortune 50 companies on quality, price, technology and service.

Risk factors

From Item 1A of the FY2025 Form 10-K, accession 0000731766-26-000062, with legal matters updated from the Q3 2026 Form 10-Q, accession 0000731766-26-000266. The 10-Q reports no material changes to the 10-K risk factors.

  • Medical cost pricing. Because nearly 80% of revenue is risk-based premium, small gaps between expected and actual medical costs move results sharply. Premiums are fixed for the contract period, so cost overruns usually cannot be recovered until the next pricing cycle. 2025 showed the risk: the company says its pricing assumptions were "well-short" of the cost trends it incurred. Results also depend on estimates of claims incurred but not yet reported; a 1% error in year-end 2025 medical costs payable would have moved 2025 net earnings by about $300 million.
  • Government program funding and audits. Medicare Advantage benchmark cuts, risk-adjustment model changes, quality bonuses that require 4-star or better ratings, Medicaid rate-setting and eligibility redeterminations, and Part D bidding against regional benchmarks all directly affect revenue. CMS and the HHS Inspector General conduct risk adjustment data validation (RADV) audits that can claw back past payments.
  • Cyberattacks and data. The company is a frequent target. Its Change Healthcare unit suffered a cyberattack in 2024 that exposed protected health information. Failures in data integrity, IT systems or AI-enabled tools, or breaches at vendors, could bring liability, regulatory penalties and lost customers.
  • Provider relationships. Hospitals and large physician groups with market power can demand higher rates or decline to contract. Out-of-network providers can dispute payments. Risk-bearing provider groups can fail financially, leaving the company responsible for claims it already paid them to cover.
  • Competition and innovation. Consolidation among competitors and suppliers, new entrants and disruptive technology threaten market share. Growth depends on moving care to value-based models that providers and payers are willing to adopt.
  • Litigation and investigations. The company faces False Claims Act, antitrust, malpractice, coverage, privacy and shareholder claims, and is largely self-insured against them. In the main pending case, filed by a whistleblower in 2011 and pursued by the US Department of Justice since 2017, the DOJ alleges improper Medicare risk-adjustment submissions. A court-appointed Special Master recommended summary judgment for the company in March 2025, the DOJ asked the court to reject that report in April 2025, and the company cannot estimate the outcome. Separately, on March 6, 2026 the IRS issued Notices of Proposed Adjustment on intercompany transfer pricing with a foreign subsidiary for tax years 2017 through 2020. The IRS seeks significant increases in taxable income and could pursue later years; the company disputes the adjustments and considers its reserves adequate.
  • Pharmacy benefit regulation. Proposed laws on rebates, formularies, pricing benchmarks and network reimbursement, and government investigations of PBM practices, could change Optum Rx's business model. Optum Rx could also face claims that it owes fiduciary duties to ERISA plans.
  • Regulatory change and publicity. Changes to the ACA, tax law, licensure or the corporate-practice-of-medicine rules can force changes in operations. The industry's negative publicity can invite further scrutiny.
  • Balance sheet risks. Goodwill and other intangible assets were $131 billion, 42% of total assets, at year-end 2025, so an impairment would be large. A credit-rating downgrade would raise borrowing costs; Moody's, S&P and Fitch all had the senior debt on negative outlook at both December 31, 2025 and September 30, 2026. Losses in the investment and loan portfolio would hurt earnings and the capital of regulated subsidiaries.
  • Dependence on regulated subsidiaries. The parent relies on dividends from state-regulated insurers to pay its debt, dividends and buybacks. In 2025 the US regulated subsidiaries received net capital infusions of $535 million, compared with net dividends of $9.2 billion paid to their parents in 2024. The 10-K also expected statutory capital requirements to rise because of the higher medical care ratio.
  • Other. Unfavorable economic conditions can cut employer coverage and state budgets. Acquisitions can bring inherited legal and IT problems. Retaining key executives, and pandemics or natural disasters, are also cited as risks.

Management's discussion of fiscal 2025

From Item 7 of the FY2025 Form 10-K, accession 0000731766-26-000062.

2025 was a year of rapid growth and collapsing margins. Revenue rose 12% to $447.6 billion: UnitedHealthcare grew 16% on Medicare Advantage enrollment, higher-acuity Medicaid members and Inflation Reduction Act changes to Part D, and Optum grew 7%. But medical costs rose 19% to $314.0 billion. The medical care ratio (medical costs divided by premiums) rose to 89.1% from 85.5%, and earnings from operations fell 41% to $19.0 billion from $32.3 billion. Net earnings attributable to shareholders were $12.1 billion against $14.4 billion, and diluted earnings per share were $13.23 against $15.51. Cash flow from operations fell to $19.7 billion from $24.2 billion.

Management attributes the higher medical care ratio to:

  • Medicare funding reductions.
  • Elevated medical cost trend.
  • The profile of patients newly added to value-based care arrangements.
  • Losses expected on certain 2026 Optum Health value-based contracts, recognized early.
  • Much smaller favorable reserve development: $140 million, against $700 million in 2024.
  • The Part D changes.
  • Higher morbidity in its individual exchange plans.

Separately, the company recognized several large items in the fourth quarter of 2025:

  • Portfolio actions: a net gain of $568 million. A $1.5 billion net gain at Optum Rx, which included a gain on deconsolidating a business, was partly offset by losses of $821 million at Optum Health and $68 million at Optum Insight.
  • Restructuring and other actions: $2.5 billion in total. This comprised $746 million for real estate rationalization and workforce reductions, $573 million of contractual reassessments, a $623 million loss contract reserve for 2026 value-based care losses, $329 million of net valuation losses on equity securities and $250 million of advance funding to the United Health Foundation.
  • Change Healthcare: a $799 million addition to reserves against the interest-free loans made to providers after the cyberattack and other customer balances.

Three of the four segments earned less operating profit; only Optum Rx earned more:

  • UnitedHealthcare: earnings from operations fell to $9.4 billion from $15.6 billion, and its operating margin halved to 2.7%.
  • Optum Health: swung to an operating loss of $278 million from earnings of $7.8 billion. Medicare Advantage funding cuts, elevated cost trends, new patient profiles, restructuring charges, the 2026 loss contract reserve and divestiture losses all contributed. Its consumers served fell to about 95 million from 100 million.
  • Optum Insight: earnings fell to $2.6 billion from $3.1 billion.
  • Optum Rx: earnings rose to $7.2 billion from $5.8 billion. The divestiture gain helped, and adjusted scripts rose to 1,659 million from 1,623 million.

UnitedHealthcare served 49.8 million people domestically at year-end, 415,000 more than a year earlier. Medicare Advantage added 600,000 members while risk-based commercial lost 680,000.

Looking into 2026, the 10-K expected a smaller company. The company expected Medicare Advantage membership to shrink as it cut benefits and raised prices, value-based care patient counts at Optum Health to fall, and Medicaid membership to drop on reduced eligibility and its exit from one state. It called the CMS Advance Notice for 2027 Medicare Advantage rates "far below" expected cost trend. At December 31, 2025 cash and investments totaled $74.7 billion, of which about $1.1 billion of cash was available for general corporate use.

Current quarter: Q3 2026

From the Q3 2026 Form 10-Q, accession 0000731766-26-000266, and the third-quarter results release furnished on Form 8-K, accession 0000731766-26-000255. Guidance history and the Alegeus transaction are also drawn from the first- and second-quarter releases, accessions 0000731766-26-000121 and 0000731766-26-000191.

In 2026 the company is serving fewer people but earning more on them. Third-quarter revenue was flat at $112.7 billion, against $113.2 billion a year earlier. Premiums fell 2% to $87.1 billion as membership shrank, while products rose 7% and services 5%. Earnings from operations rose 52% to $6.6 billion from $4.3 billion. Net earnings attributable to shareholders were $4.1 billion against $2.3 billion, and diluted EPS was $4.56 against $2.59; adjusted EPS (a non-GAAP measure) was $4.69 against $2.92. The medical care ratio improved to 88.4% from 89.9%. Management credits medical cost management initiatives, benefit design changes, pricing and favorable prior-period reserve development, which the release puts at $610 million in the quarter, related to 2026 dates of service. The operating cost ratio fell to 12.8% from 13.5%. For the nine months, revenue was $336.4 billion (up 1%), earnings from operations $23.5 billion (against $18.6 billion), diluted EPS $17.50 (against $13.21) and operating cash flow $25.1 billion (against $18.6 billion).

Membership is contracting. UnitedHealthcare served 48.3 million people at September 30, 2026, 1.8 million fewer than a year earlier:

  • Medicare Advantage: down 830,000 (10%) to 7.6 million.
  • Medicaid: down 765,000 (10%) to 6.7 million, on reduced eligibility and the exit from one state.
  • Risk-based commercial: down 865,000 (10%).
  • Fee-based commercial: up 690,000 (3%), partly offsetting the losses.

By segment, third quarter 2026 against third quarter 2025:

  • UnitedHealthcare: revenue of $86.3 billion was down 1%. Earnings from operations were $2.8 billion against $1.8 billion, and the operating margin rose to 3.3% from 2.1%, on pricing, benefit changes, reserve development and cost management.
  • Optum Health: revenue of $22.9 billion was down 10% on fewer value-based care patients and dispositions. Earnings from operations were $735 million against $41 million, helped by cost management, pricing, favorable reserve development, a $62 million net benefit from restructuring and other items, and divestiture gains. It served about 92 million consumers, against 93 million on the recast basis.
  • Optum Insight: revenue of $5.5 billion was up 3%. Earnings from operations were $1.3 billion against $920 million, a 23.4% margin, on higher investment income and growth in business and technology services.
  • Optum Rx: revenue of $39.9 billion was up 1%. Earnings from operations were $1.7 billion against $1.5 billion, on specialty pharmacy growth and biosimilar adoption, even though adjusted scripts fell to 393 million from 414 million as UnitedHealthcare and other customers lost members.

Trends management flags. Commercial medical cost trend remains elevated, which the company attributes in part to the No Surprises Act's independent dispute resolution process and more aggressive provider billing. It has voluntarily pledged to rebate its 2026 profits on individual ACA exchange plans; the release says this returns money to about 1 million members. Medicaid rates still lag the acuity of members, keeping margins under pressure. The CMS Final Notice for 2027 Medicare Advantage rates "moved towards" expected cost trend but remains below it. The release reports that at least 69% of Medicare Advantage members are in 4-star or better plans for 2027.

Portfolio and restructuring follow-through. The fourth-quarter 2025 portfolio actions produced net gains of $224 million in the quarter and $415 million year to date. In the first nine months the company sold businesses it had classified as held for sale for $1.1 billion of cash. The net gain was $211 million: a $525 million gain at Optum Insight less a $314 million loss at Optum Health. The company made a single $400 million contribution to the United Health Foundation in the first quarter. The first-quarter release (0000731766-26-000121) ties it both to the net proceeds of the Optum UK sale and to the cash gain on the disposition of an Optum Insight business, and the 10-Q describes it as proceeds from the disposition within Optum Insight; no filing says outright that the Optum UK business sat within Optum Insight. The loss contract reserve set up for 2026 value-based care losses was reduced by $95 million in the quarter and $282 million year to date. The sale of the remaining South American operations is now expected to close in the fourth quarter of 2026; the 10-K had said the second half of 2026.

Acquisition of Alegeus. On July 2, 2026 Optum Insight completed its acquisition of Alegeus Technologies, which provides benefits administration for consumer-directed health care accounts. The 10-Q, which does not name the business, puts the price of the acquisition completed that day at $3.0 billion: $1.5 billion in cash, with the remaining $1.5 billion payable within one year and still outstanding at September 30, 2026. The first-quarter release had said the deal was expected to be earnings neutral to 2026.

Guidance has been raised every quarter this year. The current 2026 outlook is GAAP EPS of at least $19.50 and adjusted EPS of at least $20.50. The history:

DateGAAP EPS outlookAdjusted EPS outlook
January 27, 2026greater than $17.10greater than $17.75
April 21, 2026greater than $17.35greater than $18.25
July 16, 2026$18.45 to $18.95$19.50 to $20.00
October 13, 2026at least $19.50at least $20.50

Capital and liquidity. Over the nine months the company repurchased about 13.8 million shares at an average $359.55. These included 6.4 million shares at $312.73 under $2.0 billion of forward contracts settled July 1, 2026. In June 2026 it raised the dividend to an annual rate of $9.28 from $8.84. Net debt repayments were $3.1 billion. The release puts the debt-to-capital ratio at 41.7% and says the company targets about 40% by year-end. At September 30, 2026 it had $2.9 billion of commercial paper outstanding at 3.9%. Cash and investments were $78.3 billion, of which $1.2 billion of cash was available for general corporate use. Its 364-day receivables financing facility stands at $2.2 billion, against the $3.3 billion facility it entered into in 2025.

Subsequent events

From the Q3 2026 Form 10-Q, accession 0000731766-26-000266 (filed November 3, 2026), and the Form 8-K furnishing the third-quarter release, accession 0000731766-26-000255.

  • Larger buyback authorization (November 2026). The Board amended the share repurchase program to authorize the repurchase of up to 50 million shares, in addition to all shares remaining under its 2024 authorization. That remaining authorization stood at 7.2 million shares at September 30, 2026.
  • Results and guidance (October 13, 2026). The company reported third-quarter results and raised its 2026 outlook to at least $19.50 GAAP EPS and at least $20.50 adjusted EPS.
  • Pending transactions. The sale of the remaining South American operations was still pending at the filing date and expected to close in the fourth quarter of 2026. The $1.5 billion deferred portion of the July 2026 Alegeus purchase price is payable within one year of the July 2, 2026 closing.

The 10-Q discloses no acquisitions, divestitures, debt issuances or litigation outcomes after September 30, 2026 other than the items above.

AI synthesis of events in 15 filings

Filings that contain financial statements

  • Form 8-K, October 13, 2026, accession 0000731766-26-000255 (Exhibit 99.1, third quarter 2026 earnings release): condensed consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025, a condensed consolidated balance sheet at September 30, 2026 (against December 31, 2025), and condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025. It also carries revenues and earnings by business, people served and performance metrics, and a non-GAAP reconciliation.
  • Form 8-K, July 16, 2026, accession 0000731766-26-000191 (Exhibit 99.1, second quarter 2026 earnings release): condensed consolidated statements of operations, balance sheet and statements of cash flows for the period ended June 30, 2026.
  • Form 8-K, April 21, 2026, accession 0000731766-26-000121 (Exhibit 99.1, first quarter 2026 earnings release): condensed consolidated statements of operations, balance sheet and statements of cash flows for the quarter ended March 31, 2026.
  • Form 8-K, January 27, 2026, accession 0000731766-26-000025 (Exhibit 99.1, fourth quarter and full year 2025 earnings release): condensed consolidated statements of operations, balance sheet and statements of cash flows for the quarter and year ended December 31, 2025.

Earnings and guidance

  • October 13, 2026 - third quarter 2026 results (0000731766-26-000255). Revenues were $112.7 billion against $113.2 billion a year earlier. Earnings from operations were $6.6 billion against $4.3 billion. Diluted earnings per share were $4.56 ($2.59 a year earlier) and adjusted earnings per share were $4.69 ($2.92). The medical care ratio was 88.4% against 89.9%, and included $610 million of net favorable prior-period reserve development tied to 2026 dates of service. The operating cost ratio was 12.8% against 13.5%. Cash flows from operations were $5.1 billion for the quarter, and the debt-to-capital ratio was 41.7% at September 30, 2026. UnitedHealthcare revenues were $86.3 billion (earnings from operations $2.8 billion) and Optum revenues were $66.9 billion (earnings from operations $3.7 billion). The company raised full-year 2026 guidance to GAAP earnings of at least $19.50 per share and adjusted earnings of at least $20.50 per share. The release reported that the company had repurchased $5.0 billion of its stock and paid $6.2 billion in dividends year to date, and that at least 69% of members are in 4+ Star Medicare Advantage plans for the 2027 Stars ratings.
  • July 16, 2026 - second quarter 2026 results (0000731766-26-000191). Revenues were $112.0 billion and earnings from operations were $8.0 billion. Earnings per share were $6.04 and adjusted earnings per share were $6.38. The medical care ratio was 86.7% and the operating cost ratio was 12.7%. Full-year 2026 guidance was raised to GAAP earnings of $18.45 to $18.95 per share and adjusted earnings of $19.50 to $20.00 per share. The release reported that Optum Insight completed its Alegeus acquisition on July 2, 2026 (see Portfolio actions).
  • April 21, 2026 - first quarter 2026 results (0000731766-26-000121). Revenues were $111.7 billion and earnings from operations were $9.0 billion. Earnings per share were $6.90 and adjusted earnings per share were $7.23. The medical care ratio was 83.9% and the operating cost ratio was 13.8%. Full-year 2026 guidance was raised to GAAP earnings of greater than $17.35 per share and adjusted earnings of greater than $18.25 per share. The release also announced the agreement to acquire Alegeus Technologies and the completed Optum UK sale (see Portfolio actions).
  • January 27, 2026 - fourth quarter and full year 2025 results with initial 2026 outlook (0000731766-26-000025). Full-year 2025 revenues were $447.6 billion (up 12%), earnings from operations were $19.0 billion, earnings were $13.23 per share and adjusted earnings were $16.35 per share. The fourth quarter showed earnings from operations of $0.4 billion against $7.8 billion a year earlier. The reported full-year medical care ratio was 89.1%. The 2026 outlook was revenues of greater than $439.0 billion, GAAP earnings of greater than $17.10 per share and adjusted earnings of greater than $17.75 per share.
  • January 12, 2026 - investor meetings (0000731766-26-000020). The company said management would reaffirm the adjusted 2025 earnings per share expectations it gave on October 28, 2025, and noted that year-end closing procedures were not yet complete.

Portfolio actions

  • The third quarter release and the Form 10-Q filed in November 2026 (accession 0000731766-26-000266) describe the portfolio actions the company began in the fourth quarter of 2025 after a strategic review. They produced gains of $224 million in the third quarter and $415 million in the first nine months of 2026, from sales of businesses previously held for sale and a gain on an asset sale, partly offset by losses on the remaining South American operations. The 10-Q states the company entered into an agreement in the fourth quarter of 2025 to sell its remaining South American operations, expected to close in the fourth quarter of 2026 subject to regulatory and other customary closing conditions. That sale is signed, not closed, as of the 10-Q. No 8-K in the period announced the agreement.
  • Alegeus Technologies acquisition - CLOSED. April 21, 2026 (0000731766-26-000121, first quarter release): the company agreed to acquire Alegeus Technologies, a health care technology platform providing benefits administration for consumer-directed health care accounts, subject to regulatory review, expected to close in the back half of 2026 and be earnings neutral to 2026. July 16, 2026 (0000731766-26-000191, second quarter release): Optum Insight completed the acquisition of Alegeus on July 2, 2026. The Form 10-Q (0000731766-26-000266, Note 7, Other Commitments) states that on July 2, 2026 the company completed an acquisition for $3.0 billion, $1.5 billion in cash and $1.5 billion payable within one year, with the payable outstanding at September 30, 2026. The 10-Q does not name the target; the price is matched to Alegeus by the shared July 2, 2026 completion date.
  • Sale of the Optum UK business - completed. April 21, 2026 (0000731766-26-000121, first quarter release): the company completed the sale of the Optum UK business, with $400 million of net proceeds committed to the United Health Foundation, as part of refocusing on U.S. health care and exiting non-U.S. businesses. The Form 10-Q (0000731766-26-000266, Note 8) states that in the first nine months of 2026 the company completed dispositions of businesses held for sale for $1.1 billion of cash, recording a net gain of $211 million ($525 million gain at Optum Insight, $314 million loss at Optum Health), and contributed $400 million of the Optum Insight disposition proceeds to the United Health Foundation. The first-quarter release ties the same $400 million contribution both to the Optum UK sale proceeds and to the cash gain on the disposition of an Optum Insight business, so it was a single contribution; the release does not say outright that Optum UK was part of Optum Insight.

Capital actions

  • Share repurchase authorization (Form 10-Q, accession 0000731766-26-000266). The 10-Q states that in November 2026 the Board amended the repurchase program to authorize up to 50 million additional shares, on top of the 7.2 million shares remaining under the 2024 renewal at September 30, 2026. This appears in the 10-Q only; no 8-K announced it.
  • Year-to-date repurchases and forward contracts (0000731766-26-000266). For the nine months ended September 30, 2026 the company repurchased about 13.8 million shares at an average $359.55, including 6.4 million shares bought at an average $312.73 under forward contracts for up to $2.0 billion that settled on July 1, 2026.

Management, board and governance

  • November 18, 2025 (8-K filed November 21, 2025, 0000731766-25-000314): Scott Gottlieb, M.D., former FDA commissioner, was appointed an independent director effective immediately.
  • November 6, 2025 (8-K filed November 13, 2025, 0000731766-25-000310): The Board amended the bylaws solely to reflect a change in the registered office and registered agent in Delaware (Exhibit 3.1).
  • February 23-25, 2026 (0000731766-26-000046): The Compensation and Human Resources Committee amended CEO Stephen Hemsley's May 14, 2025 stock option to add a two-year holding requirement on net exercised shares until May 14, 2030, after the three-year cliff vesting.
  • March 2, 2026 (0000731766-26-000064): Dennis Stankiewicz, the Corporate Controller, was appointed Chief Accounting Officer effective March 2, 2026, with an annual base salary of $550,000.
  • June 5, 2026 (annual meeting held June 1, 2026; 0000731766-26-000138): All nine directors were elected, with support of 89.68% to 98.96% of votes cast. Say-on-pay was approved with 82.74% of votes for. Deloitte & Touche LLP was ratified as auditor. A shareholder proposal to require an independent board chair was not approved (20.24% in favor).
  • Form 10-Q, accession 0000731766-26-000266. The Department of Justice's False Claims Act risk-adjustment suit, first pursued in 2017, remains unresolved. A Special Master recommended in March 2025 that summary judgment be entered for the company, and the DOJ asked the court to reject that report in April 2025. The company says it cannot reasonably estimate the outcome. The 10-Q also states that on March 6, 2026 the company received IRS Notices of Proposed Adjustment for the 2017 through 2020 tax years, concerning intercompany transfer pricing with a foreign subsidiary. The IRS is seeking to significantly increase taxable income. The company disagrees and intends to contest it, and believes its reserves are adequate at September 30, 2026. Neither matter was the subject of an 8-K in this period.

Routine disclosures

Investor-conference webcast notices (Regulation FD) were filed for the UBS Global Healthcare Conference (November 10, 2025; 0000731766-25-000308), Barclays Global Healthcare Conference (March 10, 2026; 0000731766-26-000067), Bank of America Securities Health Care Conference (May 12, 2026; 0000731766-26-000129) and Wells Fargo Healthcare Conference (September 9, 2026; 0000731766-26-000205). They carry no financial news.

Financials

Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.

About this file

TickerUNH
CIK0000731766
CompanyUnitedHealth Group Incorporated
Business typehealthcare
Schema templateDiversified health care (health benefits plus health services): revenue split the way the company reports it (premiums, products, services, investment and other income); operating costs split into medical costs, operating costs, cost of products sold and depreciation and amortization; earnings from operations, net earnings and per-share figures; the medical care ratio the company reports (medical costs divided by premium revenue); and a balance sheet and cash flow on the company's own lines. Gross profit is not used because the company does not present one.
Reporting currencyUSD
Converted to USDno
Unitsactual dollars (not millions); share counts in actual shares (not millions); per-share amounts in dollars; ratios in percent. Figures keep the sign the statement prints: amounts shown in parentheses (interest expense, income tax provision, cash outflows) are negative.

UNH annual income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

FY2025FY2024FY2023
Period start2025-01-012024-01-012023-01-01
Period end2025-12-312024-12-312023-12-31
Period typefiscal yearfiscal yearfiscal year
Source accession10-K10-K10-K
Income statement
Premiums352,229,000,000308,810,000,000290,827,000,000
Products revenue53,380,000,00050,226,000,00042,583,000,000
Services revenue38,038,000,00036,040,000,00034,123,000,000
Investment and other income3,920,000,0005,202,000,0004,089,000,000
Total revenues447,567,000,000400,278,000,000371,622,000,000
Medical costs313,995,000,000264,185,000,000241,894,000,000
Operating costs59,592,000,00053,013,000,00054,628,000,000
Cost of products sold50,655,000,00046,694,000,00038,770,000,000
Depreciation and amortization4,361,000,0004,099,000,0003,972,000,000
Total operating costs428,603,000,000367,991,000,000339,264,000,000
Operating income18,964,000,00032,287,000,00032,358,000,000
Interest expense-4,002,000,000-3,906,000,000-3,246,000,000
Loss on sale of subsidiary and subsidiaries held for sale-265,000,000-8,310,000,0000
Earnings before income taxes14,697,000,00020,071,000,00029,112,000,000
Provision for income taxes-1,890,000,000-4,829,000,000-5,968,000,000
Net earnings12,807,000,00015,242,000,00023,144,000,000
Earnings attributable to noncontrolling interests-751,000,000-837,000,000-763,000,000
Net earnings attributable to unitedhealth group common shareholders12,056,000,00014,405,000,00022,381,000,000
Basic EPS13.2815.6424.12
Diluted EPS13.2315.5123.86
Basic shares908,000,000921,000,000928,000,000
Diluted shares911,000,000929,000,000938,000,000
Cash flow
Cash flows from operating activities19,697,000,00024,204,000,00029,068,000,000
Capital expenditures-3,622,000,000-3,499,000,000-3,386,000,000
Cash paid for acquisitions net of cash assumed-4,509,000,000-13,408,000,000-10,136,000,000
Cash flows used for investing activities-8,685,000,000-20,527,000,000-15,574,000,000
Common share repurchases-5,545,000,000-9,000,000,000-8,000,000,000
Cash dividends paid-7,916,000,000-7,533,000,000-6,761,000,000
Cash flows used for financing activities-11,644,000,000-3,512,000,000-11,529,000,000
Free cash flow16,075,000,00020,705,000,00025,682,000,000
Key metrics
Medical care ratio percent89.185.583.2
Cash dividends paid per share8.738.187.29
Balance sheet
Cash and cash equivalents24,365,000,00025,312,000,000
Short term investments3,756,000,0003,801,000,000
Accounts receivable net23,018,000,00022,365,000,000
Other current receivables net29,697,000,00026,089,000,000
Prepaid expenses and other current assets9,746,000,0008,212,000,000
Total current assets90,582,000,00085,779,000,000
Long term investments54,251,000,00052,354,000,000
Property equipment and capitalized software net10,762,000,00010,553,000,000
Goodwill110,499,000,000106,734,000,000
Other intangible assets net20,474,000,00023,268,000,000
Other assets23,013,000,00019,590,000,000
Total assets309,581,000,000298,278,000,000
Medical costs payable39,337,000,00034,224,000,000
Accounts payable and accrued liabilities38,032,000,00034,337,000,000
Short term borrowings and current maturities of long term debt6,069,000,0004,545,000,000
Unearned revenues3,413,000,0003,317,000,000
Other current liabilities28,046,000,00027,346,000,000
Total current liabilities114,897,000,000103,769,000,000
Long term debt less current maturities72,320,000,00072,359,000,000
Deferred income taxes2,421,000,0003,620,000,000
Other liabilities18,245,000,00015,939,000,000
Total liabilities207,883,000,000195,687,000,000
Redeemable noncontrolling interests1,608,000,0004,323,000,000
Nonredeemable noncontrolling interests5,980,000,0005,610,000,000
Total equity100,090,000,00098,268,000,000
Common shares outstanding906,000,000915,000,000
Total debt78,389,000,00076,904,000,000

UNH quarterly income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

Q3 FY2026Q3 FY2025
Period start2026-07-012025-07-01
Period end2026-09-302025-09-30
Period typethree monthsthree months
Source accession10-Q10-Q
Fiscal quarter33
Income statement
Premiums87,078,000,00088,979,000,000
Products revenue14,293,000,00013,296,000,000
Services revenue10,246,000,0009,754,000,000
Investment and other income1,077,000,0001,132,000,000
Total revenues112,694,000,000113,161,000,000
Medical costs76,982,000,00079,958,000,000
Operating costs14,369,000,00015,223,000,000
Cost of products sold13,707,000,00012,566,000,000
Depreciation and amortization1,073,000,0001,099,000,000
Total operating costs106,131,000,000108,846,000,000
Operating income6,563,000,0004,315,000,000
Interest expense-963,000,000-1,003,000,000
Loss on sale of subsidiary and subsidiaries held for sale-76,000,000-83,000,000
Earnings before income taxes5,524,000,0003,229,000,000
Provision for income taxes-1,224,000,000-686,000,000
Net earnings4,300,000,0002,543,000,000
Earnings attributable to noncontrolling interests-190,000,000-195,000,000
Net earnings attributable to unitedhealth group common shareholders4,110,000,0002,348,000,000
Basic EPS4.582.59
Diluted EPS4.562.59
Basic shares897,000,000906,000,000
Diluted shares902,000,000908,000,000
Key metrics
Medical care ratio percent88.489.9
Cash dividends paid per share2.322.21
Balance sheet
Common shares outstanding896,000,000
Cash and cash equivalents25,845,000,000
Short term investments2,704,000,000
Accounts receivable net20,543,000,000
Other current receivables net27,577,000,000
Prepaid expenses and other current assets8,926,000,000
Total current assets85,595,000,000
Long term investments58,064,000,000
Property equipment and capitalized software net10,950,000,000
Goodwill112,974,000,000
Other intangible assets net20,377,000,000
Other assets24,822,000,000
Total assets312,782,000,000
Medical costs payable39,352,000,000
Accounts payable and accrued liabilities39,560,000,000
Short term borrowings and current maturities of long term debt5,617,000,000
Unearned revenues3,397,000,000
Other current liabilities27,909,000,000
Total current liabilities115,835,000,000
Long term debt less current maturities68,714,000,000
Deferred income taxes2,528,000,000
Other liabilities20,160,000,000
Total liabilities207,237,000,000
Redeemable noncontrolling interests1,416,000,000
Nonredeemable noncontrolling interests6,033,000,000
Total equity104,129,000,000
Total debt74,331,000,000

UNH year-to-date income statement and cash flow

Taken from the SEC filings and normalized to actual dollars.

Nine months ended September 30, 2026Nine months ended September 30, 2025
Period start2026-01-012025-01-01
Period end2026-09-302025-09-30
Period typenine monthsnine months
Source accession10-Q10-Q
Income statement
Premiums261,595,000,000263,418,000,000
Products revenue41,378,000,00039,896,000,000
Services revenue30,043,000,00027,765,000,000
Investment and other income3,431,000,0003,273,000,000
Total revenues336,447,000,000334,352,000,000
Medical costs225,829,000,000231,954,000,000
Operating costs44,027,000,00042,595,000,000
Cost of products sold39,905,000,00037,975,000,000
Depreciation and amortization3,142,000,0003,244,000,000
Total operating costs312,903,000,000315,768,000,000
Operating income23,544,000,00018,584,000,000
Interest expense-2,880,000,000-3,028,000,000
Loss on sale of subsidiary and subsidiaries held for sale-209,000,000-139,000,000
Earnings before income taxes20,455,000,00015,417,000,000
Provision for income taxes-4,004,000,000-2,828,000,000
Net earnings16,451,000,00012,589,000,000
Earnings attributable to noncontrolling interests-577,000,000-543,000,000
Net earnings attributable to unitedhealth group common shareholders15,874,000,00012,046,000,000
Basic EPS17.5813.27
Diluted EPS17.5013.21
Basic shares902,000,000908,000,000
Diluted shares906,000,000912,000,000
Cash flow
Cash flows from operating activities25,087,000,00018,589,000,000
Capital expenditures-2,421,000,000-2,674,000,000
Cash paid for acquisitions net of cash assumed-1,538,000,000-4,436,000,000
Cash flows used for investing activities-8,818,000,000-6,074,000,000
Common share repurchases-5,031,000,000-5,545,000,000
Cash dividends paid-6,170,000,000-5,914,000,000
Cash flows used for financing activities-15,033,000,000-10,613,000,000
Free cash flow22,666,000,00015,915,000,000
Key metrics
Medical care ratio percent86.388.1
Cash dividends paid per share6.856.52

UNH trailing twelve month income statement and cash flow

Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.

Twelve months ended September 30, 2026
Period start2025-10-01
Period end2026-09-30
Period typetrailing twelve months
Source accession10-Q
Source accessions10-K, 10-Q
Income statement
Premiums350,406,000,000
Products revenue54,862,000,000
Services revenue40,316,000,000
Investment and other income4,078,000,000
Total revenues449,662,000,000
Medical costs307,870,000,000
Operating costs61,024,000,000
Cost of products sold52,585,000,000
Depreciation and amortization4,259,000,000
Total operating costs425,738,000,000
Operating income23,924,000,000
Earnings before income taxes19,735,000,000
Net earnings16,669,000,000
Net earnings attributable to unitedhealth group common shareholders15,884,000,000
Cash flow
Cash flows from operating activities26,195,000,000
Capital expenditures-3,369,000,000
Free cash flow22,826,000,000
  • Derivation. Computed, not printed in either filing: full year 2025 from the FY2025 10-K (accession 0000731766-26-000062), plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the Q3 2026 10-Q (accession 0000731766-26-000266).

Adjustments

Splits appliednone
ADR ration/a
FXnone; the company reports in US dollars

Notes

  • Sources: the three fiscal years (2023, 2024, 2025) and the December 31, 2025 and 2024 balance sheets come from the FY2025 Form 10-K (accession 0000731766-26-000062, filed March 2, 2026). The quarters ended September 30, 2026 and September 30, 2025, the nine-month periods and the September 30, 2026 balance sheet come from the Q3 2026 Form 10-Q (accession 0000731766-26-000266, filed November 3, 2026).
  • The 10-Q's December 31, 2025 balance sheet column matches the 10-K's balance sheet line for line.
  • Line items follow the company's own statement captions. operating_income is the line the company labels "Earnings from operations". net_earnings_attributable_to_unitedhealth_group_common_shareholders is the figure earnings per share is based on; net_earnings includes the share belonging to noncontrolling interests.
  • Signs follow the statements: interest expense, the provision for income taxes, the loss on sale of subsidiaries, earnings attributable to noncontrolling interests and every cash outflow are printed in parentheses and are stored as negative numbers.
  • medical_care_ratio_percent is the medical care ratio as printed in the results summary of each filing's Management's Discussion and Analysis, which the company defines as medical costs divided by premium revenue.
  • capital_expenditures is the cash flow line "Purchases of property, equipment and capitalized software". cash_paid_for_acquisitions_net_of_cash_assumed is the line "Cash paid for acquisitions and other transactions, net of cash assumed".
  • Computed figures, not printed in the filings: free_cash_flow is cash flows from operating activities less purchases of property, equipment and capitalized software; total_debt is "Short-term borrowings and current maturities of long-term debt" plus "Long-term debt, less current maturities". The trailing-twelve-month block is also computed, as described in that block.
  • common_shares_outstanding is the share count on the closing balance rows of the statement of changes in equity, printed in millions (896 million at September 30, 2026). The 10-Q cover reports 896,022,611 shares outstanding as of October 30, 2026.
  • cash_dividends_paid_per_share is taken from the statement of changes in equity, which prints it in the caption of the cash dividends row (for example, "Cash dividends paid on common shares ($ 2.32 per share)" for the third quarter of 2026, and $6.85 per share for the first nine months of 2026).
  • Diluted earnings per share for the first nine months of 2026 ($17.50) is slightly below net earnings attributable to common shareholders divided by diluted shares. The 10-Q explains that the calculation of basic and diluted earnings per share includes an immaterial reduction to net earnings attributable to common shareholders for undistributed earnings attributable to shares held by the counterparty to forward share repurchase contracts, which covered 6.4 million shares and were settled on July 1, 2026.
  • The 10-Q presents its cash flow statement for the nine months ended September 30 only, so the two quarters carry no cash flow block; the nine-month cash flows are in year_to_date. The company's third-quarter 2026 earnings release (Form 8-K, accession 0000731766-26-000255) states that cash flows from operations for the quarter were $5.1 billion, a rounded figure that is not reproduced as a line item here.
  • The 10-Q prints no September 30, 2025 balance sheet, and the 10-K prints no December 31, 2023 balance sheet, so those periods carry none.
  • No stock split, currency translation or depositary-share adjustment applies: the company reports in US dollars, its common stock trades directly on the NYSE, and it has had no stock split in the periods covered.

Uncertainties

  • Three-month cash flow figures for the third quarters of 2026 and 2025 are not given here. The 10-Q prints cash flows only for the nine-month periods, and the six-month figures needed to separate out the third quarter are not in these two filings.
  • Weighted-average share counts are printed rounded to the nearest million, so dividing net earnings by them reproduces the printed earnings per share only approximately.

Company details

NameUnitedhealth Group Inc
TickerUNH
CIK0000731766
ExchangeNYSE
StateMinnesota
IncorporationDelaware
SIC6324
OfficeFinance
IndustryHospital & Medical Service Plans

Fiscal period

Fiscal year2026
Fiscal periodQ3
TagFY26Q3
Period end2026-09-30
Form10-Q
Accession0000731766-26-000266
Fiscal year end1231
Sourcefacts

Source filings

RoleCurrentFormFiscal yearFiscal periodTagPeriod endFiledAccessionSource
annualno10-K2025FYFY252025-12-312026-03-020000731766-26-000062reported
quarterlyyes10-Q2026Q3FY26Q32026-09-302026-11-030000731766-26-000266facts

Related companies

See every covered company and its filings data.

Not investment advice, see the Disclaimer.